Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations (Unaudited)

v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Product Revenue
Product Cost of Sales
Gross Profit
General and Administrative Expenses 1,066,650 841,685
Research and Development Expenses 510,534 1,545,513
Stock Based Compensation Expenses 58,606 84,636
Franchise Tax Expense 219,403
Loss from Operations (1,855,193) (2,471,834)
Other (Income) Expenses    
Interest and Dividend Income (71,340) (62,512)
Gain on Sale of Investments (11,782) (2,176)
Unrealized (Gain) Loss on Marketable Securities (19,294) 1,597
Change in fair value of Derivatives Liabilities (510,000) (1,284,000)
Total Other Income (612,416) (1,347,091)
Loss Before Income Tax (1,242,777) (1,124,743)
Income Tax Benefit/(Provision)
Net Loss (1,242,777) (1,124,743)
Preferred Stock Dividends 285,671 813,496
Net Loss Attributable to Common Stockholders $ (1,528,448) $ (1,938,239)
Basic net loss per common share $ (0.19) $ (0.36)
Diluted net loss per common share $ (0.19) $ (0.36)
Weighted average basic common stock outstanding 8,059,560 5,349,662
Weighted average diluted common stock outstanding 8,059,560 5,349,662